2020 Revenues ($USD) : $24,539,800,000
2020 R&D spend : $6,086,000,000
2020 Number of Employees : 35,000
Fiscal Year End : 12/31/2020
Key People : David A. Ricks, chairman and CEO; Anat Ashkenazi, senior vice president and chief financial officer; Melissa Stapleton Barnes, Senior Vice President, Enterprise Risk Management, and Chief Ethics and Compliance Officer; Stephen F. Fry, Senior Vice President, Human Resources and Diversity; Anat Hakim, Senior Vice President, General Counsel and Secretary; Patrik Jonsson, Senior Vice President; President, Lilly USA; and Chief Customer Officer; Michael B. Mason, Senior Vice President and President, Lilly Diabetes; Johna L. Norton, Senior Vice President, Global Quality; Myles O'Neill, Senior Vice President and President, Manufacturing Operations; Leigh Ann Pusey, Senior Vice President, Corporate Affairs and Communications; Aarti Shah, Senior Vice President and Chief Information and Digital Officer; Dr. Daniel M. Skovronsky, Senior Vice President and Chief Scientific Officer; Anne E. White, Senior Vice President and President, Lilly Oncology; Ilya Yuffa, Senior Vice President and President, Lilly Bio-Medicines; Alfonso Zulueta, Senior Vice President and President, Lilly International

Eli Lilly was founded in 1876 and has 24 drugs that it currently manufactures and distributes in 120 countries. The Indianapolis-based company makes drugs for diabetes, oncology, immunology, neurosciences and other therapies, including COVID-19 treatment therapies. Eli Lilly picked up two companies in the last year. It bought Prevail Therapeutics for $880 million in January this year and Disarm Therapeutics for $135 million in October 2020. Last year, Eli Lilly won FDA approval for a couple of its drugs, including additional doses of its Trulicity drug to treat type 2 diabetes, Cyramza for treating metastatic EGFR-mutated non-small cell lung cancer and Tauvid for patients evaluated for Alzheimer's disease. –DK